martes, 31 de octubre de 2017

Journal for ImmunoTherapy of Cancer | Basic Tumor Immunology

Journal for ImmunoTherapy of Cancer | Basic Tumor Immunology

Biomed Central

JITC logo

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Previous Page Page 1 of 2 Next Page

    Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...
    Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young
    Journal for ImmunoTherapy of Cancer 2017 5:69
    Published on: 15 August 2017

    Tumor-derived exosomes induce CD8+ T cell suppressors

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...
    Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman
    Journal for ImmunoTherapy of Cancer 2017 5:65
    Published on: 15 August 2017

    The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...
    Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson
    Journal for ImmunoTherapy of Cancer 2017 5:63
    Published on: 15 August 2017

    Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...
    Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif
    Journal for ImmunoTherapy of Cancer 2017 5:64
    Published on: 15 August 2017

    GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory

    The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...
    Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow and Scott H. Robbins
    Journal for ImmunoTherapy of Cancer 2017 5:47
    Published on: 20 June 2017

    Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice

    Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...
    Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese and Bryon D. Johnson
    Journal for ImmunoTherapy of Cancer 2017 5:51
    Published on: 20 June 2017

    A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...
    Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas
    Journal for ImmunoTherapy of Cancer 2017 5:42
    Published on: 16 May 2017

    Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...
    Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita
    Journal for ImmunoTherapy of Cancer 2017 5:9
    Published on: 21 February 2017

    Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

    Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...
    James T. Gordy, Kun Luo, Hong Zhang, Arya Biragyn and Richard B. Markham
    Journal for ImmunoTherapy of Cancer 2016 4:96
    Published on: 20 December 2016

    Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases

    Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...
    Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter and Ekaterina S. Jordanova
    Journal for ImmunoTherapy of Cancer 2016 4:78
    Published on: 15 November 2016

    Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

    Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...
    Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour
    Journal for ImmunoTherapy of Cancer 2016 4:68
    Published on: 18 October 2016

    Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape

    Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...
    Itsaso Montalbán del Barrio, Cornelia Penski, Laura Schlahsa, Roland G. Stein, Joachim Diessner, Achim Wöckel, Johannes Dietl, Manfred B. Lutz, Michel Mittelbronn, Jörg Wischhusen and Sebastian F. M. Häusler
    Journal for ImmunoTherapy of Cancer 2016 4:49
    Published on: 16 August 2016

    Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5

    Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...
    Jason W.-L. Eng, Thomas A. Mace, Rohit Sharma, Danielle Y. F. Twum, Peng Peng, John F. Gibbs, Rosemarie Pitoniak, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky and Bonnie L. Hylander
    Journal for ImmunoTherapy of Cancer 2016 4:33
    Published on: 21 June 2016

    Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient

    Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...
    Imran Siddiqui, Marco Erreni, Mandy van Brakel, Reno Debets and Paola Allavena
    Journal for ImmunoTherapy of Cancer 2016 4:21
    Published on: 19 April 2016

    Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

    Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...
    Michelle H. Nelson, Jacob S. Bowers, Stefanie R. Bailey, Marshall A. Diven, Caroline W. Fugle, Andrew D. M. Kaiser, Claudia Wrzesinski, Bei Liu, Nicholas P. Restifo and Chrystal M. Paulos
    Journal for ImmunoTherapy of Cancer 2016 4:6
    Published on: 16 February 2016

    Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma

    A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...
    Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon
    Journal for ImmunoTherapy of Cancer 2016 4:10
    Published on: 16 February 2016

    Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant

    Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...
    Brian M. Andersen, Junzhe Xia, Alan L. Epstein, John R. Ohlfest, Wei Chen, Bruce R. Blazar, Christopher A. Pennell and Michael R. Olin
    Journal for ImmunoTherapy of Cancer 2016 4:11
    Published on: 16 February 2016

    Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

    Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...
    Anders Olsson, Jessica Nakhlé, Anette Sundstedt, Pascale Plas, Anne-Laure Bauchet, Valérie Pierron, Luce Bruetschy, Adnan Deronic, Marie Törngren, David Liberg, Fabien Schmidlin and Tomas Leanderson
    Journal for ImmunoTherapy of Cancer 2015 3:53
    Published on: 15 December 2015

    Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors

    Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...
    Joanne A. Hammill, Heather VanSeggelen, Christopher W. Helsen, Galina F. Denisova, Carole Evelegh, Daniela G. M. Tantalo, Jennifer D. Bassett and Jonathan L. Bramson
    Journal for ImmunoTherapy of Cancer 2015 3:55
    Published on: 15 December 2015

    Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab

    Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...
    Venky Ramakrishna, Karuna Sundarapandiyan, Biwei Zhao, Max Bylesjo, Henry C. Marsh and Tibor Keler
    Journal for ImmunoTherapy of Cancer 2015 3:37
    Published on: 18 August 2015

No hay comentarios:

Publicar un comentario